Bone loss in patients treated with pulses of methylprednisolone is not negligible: A short term prospective observational study

Annals of the Rheumatic Diseases

Volumn 63, Issue 8, 2004, Pages 940-944

  Haugeberg, G ^b   Griffiths, B ^b   Sokoll, K B ^b   Emery, P ^a,b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ESTROGEN; METHYLPREDNISOLONE; PREDNISOLONE;

ADULT; AGED; ARTICLE; BODY MASS; BONE DENSITY; BONE DISEASE; BONE MASS; BONE MINERAL; CLINICAL ARTICLE; DEMOGRAPHY; DISEASE DURATION; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; INFORMATION PROCESSING; LUMBAR SPINE; MALE; OSTEOLYSIS; PRIORITY JOURNAL; RHEUMATIC DISEASE;

ADULT; AGED; BONE DENSITY; DENSITOMETRY, X-RAY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLPREDNISOLONE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 3242700399     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.011734     Document Type: Article

References (29)

1. Illei GG, Austin HA, Crane M, Collins L, Gourley MF, Yarboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248-57.
2. Haugeberg G, Bie R, Bendvold A, Larsen AS, Johnsen V. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol 1998;17:364-8.
3. van der Veen MJ, Bijlsma JW. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. Clin Rheumatol 1993;12:500-5.
4. Bijlsma JW, Duursma SA, Huber-Bruning O. Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Ann Rheum Dis 1986;45:757-60.
5. van der Veen MJ, Bijlsma JW. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin Rheumatol 1992;11:388-92.
6. Lems WF, Gerrits MI, Jacobs JW, van Vugt RM, van Rijn HJ, Bijlsma JW. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. Ann Rheum Dis 1996;55:288-93.
7. Mier RJ. Prevention of corticosteroid induced osteoporosis. J Rheumatol 1997;24:407.
8. Adu D, Pall A, Luqmani RA, Richards KT, Howie AJ, Emery P, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. Q J Med 1997;90:401-9.
9. Hutchinson RM, Edworthy SM. A comparison of the erythrocyte sedimentation rate and plasma viscosity in detecting changes in plasma proteins. J Clin Pathol 1977;30:345-9.
10. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 2000;43:522-30.
11. Haugeberg G, Uhlig T, Falch JA, Halse JI, Kvien TK. Reduced bone mineral density in male rheumatoid arthritis patients: frequencies and associations with demographic and disease variables in ninety-four patients in the Oslo County Rheumatoid Arthritis Register. Arthritis Rheum 2000;43:2776-84.
12. Homik J, Cranney A, Shea B, Tugwell P, Wells G, Adachi R, et al. Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst Rev 2000:CD001347.
13. Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, et al. Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000:CD001983.
14. Homik J, Suarez-Almazor ME, Shea B, Cranney A, Wells G, Tugwell P. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2000:CD000952.
15. Adachi JD, Bensen WG, Brown J, Hanley D, Hodsman A, Josse R, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
16. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998;339:292-9.
17. Cohen S, Levy RM, Keller M, Boling E, Emkey RD, Greenwald M, et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999;42:2309-18.
18. ACR. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. American College of Rheumatology Task Force on Osteoporosis Guidelines. Arthritis Rheum 1996;39:1791-801.
19. Adachi JD, Olszynski WP, Hanley DA, Hodsman AB, Kendler DL, Siminoski KG, et al. Management of corticosteroid-induced osteoporosis. Semin Arthritis Rheum 2000;29:228-51.
20. Boulos P, Adachi JD. Guidelines for the prevention and therapy of glucocorticoid induced osteoporosis. Clin Exp Rheumatol 2000;18:S79-86.
21. ACR. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 2001;44:1496-503.
22. Sambrook PN. Corticosteroid induced osteoporosis. J Rheumatol 1996;45(suppl):19-22.
23. Sambrook P, Lane NE. Corticosteroid osteoporosis. Best Pract Res Clin Rheumatol 2001;15:401-13.
24. Holl GM, Spector TD, Griffin AJ, Jawad AS, Hall ML, Doyle DV. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. Arthritis Rheum 1993;36:1510-16.
25. Dolan AL, Moniz C, Dasgupta B, Li F, Mackintosh C, Todd P, et al. Effects of inflammation and treatment on bone turnover and bone mass in polymyalgia rheumatica. Arthritis Rheum 1997;40:2022-9.
26. Haugeberg G, Myklebust G, Dovland H, Mikkelsen B, Gran JT. No permanent reduction in bone mineral density during treatment of polymyalgia rheumatica and temporal arteritis using low dose corticosteroids. Scand J Rheumatol 2000;29:163-9.
27. Pocock NA, Eisman JA, Dunstan CR, Evans RA, Thomas DH, Huq NL. Recovery from steroid-induced osteaporosis. Ann Intern Med 1987;107:319-23.
28. Kvien TK, Mikkelsen K, Nordvåg BY. Results from controlled clinical trials: how relevant for clinical practice? J Rheumatol 2003;30:1135-7.
29. Haugeberg G, Orstavik R, Uhlig T, Falch J A, Halse JI, Kvien TK. Bone loss in patients with rheumatoid arthritis. Results from a population based cohort of 366 patients followed over two years. Arthritis Rheum 2003;46:1720-8.